Statin therapy fails to slow progression of atherosclerosis in pediatric lupus patients

Atorvastatin therapy was found to be ineffective in reducing atherosclerosis progression in children and adolescents with systemic lupus erythematosus (SLE). Results of the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) Trial, now available in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR), report that the statin therapy did trend toward positive effect of treatment and may benefit patients with more severe SLE who were not included in the trial.

The ACR reports that SLE affects 322,000 adult Americans. Exact figures for pediatric SLE cases are difficult to establish, but the best estimate is that 5,000 to 10,000 children in the U.S. have lupus (Lehman 1996). One of the long-term complications of SLE for both adult and pediatric is accelerated atherosclerosis—a build-up of plaque in the aterial wall which can lead to heart attack and stroke. Medical evidence reports that SLE patients are up to 8 times more likely to develop premature coronary heart disease, compared to the general population. Women with lupus are 50 times more likely to have a heart attack than healthy premenopausal women.

"The prognosis for pediatric patients has significantly improved over the last few decades, however diagnosis at an earlier age subjects these patients to greater cardiovascular risk from systemic and treatment side effects over a longer time period," explains lead investigator, Dr. Laura Schanberg with the Department of Pediatrics at Duke University Medical Center in Durham, North Carolina. Previous studies show children with SLE have more severe organ damage, and longer exposure to illness and potentially toxic treatments compared with adults.

Prevalence of atherosclerosis in pediatric SLE is unknown, but precursors of the disease such as thickening of aterial artery walls as measured by carotid intima-media thickening (CIMT), have been reported. Statins have been shown to reduce atherosclerosis progression in adults, but have not been investigated in a pediatric SLE population. The APPLE Trial assessed 36-month therapy with atorvastatin, commercially known as Lipitor®, in 221 SLE patients between 10 and 21 years of age at 21 sites in North America. Participants were randomized, with 113 receiving treatment with atorvastatin and 108 a placebo at 10 or 20 mg/day (depending on weight). Researchers determined effectiveness of therapy by progression CIMT as measured by ultrasound.

"Our results demonstrate no significant effect on progression of atherosclerosis in children and with SLE who were treated with atorvastatin use over the 3-year period," concluded Dr. Christy Sandborg from Stanford University School of Medicine in California and co-primary investigator of the Apple Trial. "Further study of subgroups of SLE patients that may benefit from is warranted." While ineffective in reducing progression of atherosclerosis in this study population, atorvastatin was determined to be safe and well tolerated.

In a related editorial also published today in & Rheumatism, Dr. Angelo Ravelli from the 1Università degli Studi di Genova and Istituto di Ricovero e Cura a Carattere Scientifico in Italy said, "Although the APPLE Trial found atorvastatin to be ineffective in pediatric SLE patients with low to moderate disease activity, a trend toward positive effect was detected. This indicates that while statin therapy may not be necessary in all SLE patients, preventative statin therapy may benefit those with more severe disease activity." Post-hoc subgroup analyses of the APPLE Trial are underway which may uncover those patient groups who may benefit from treatment with .

More information: "Use of Atorvastatin in Systemic Lupus Erythematosus in Children and Adolescents." L. E. Schanberg, C. Sandborg, H. X. Barnhart, S. P. Ardoin, E. Yow, G. W. Evans, K. L. Mieszkalski, N. T. Ilowite, A. Eberhard, L. F. Imundo, Y. Kimura, E. von Scheven, E. Silverman, S. L. Bowyer, L. Punaro, N. G. Singer, D. D. Sherry, D. McCurdy, M. Klein-Gitelman, C. Wallace, R. Silver, L. Wagner-Weiner, G. C. Higgins, H. I. Brunner, L. Jung, J. B. Soep, A. M. Reed, J. Provenzale, and S. D. Thompson. Arthritis & Rheumatism; Published Online: Oct. 27, 2011 (DOI: 10.1002/art.30645).

Editorial: "Should Children and Adolescents with Systemic Lupus Erythematosus be Given Statin Therapy to Prevent Early Atherosclerosis?" Angelo Ravelli. Arthritis & Rheumatism; Published Online: Oct. 27, 2011 (DOI: 10.1002/art.30642).

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Sierra Leone faces criticism over Ebola shutdown

10 minutes ago

Sierra Leone began the second day of a 72-hour nationwide shutdown aimed at containing the spread of the deadly Ebola virus on Saturday amid criticism that the action was a poorly planned publicity stunt.

Presence of peers ups health workers' hand hygiene

14 hours ago

(HealthDay)—The presence of other health care workers improves hand hygiene adherence, according to a study published in the October issue of Infection Control and Hospital Epidemiology.

Sierra Leone streets deserted as shutdown begins

22 hours ago

Sierra Leone's normally chaotic capital resembled a ghost town on Friday as residents were confined to their homes for the start of a three-day lockdown aimed at halting the deadly Ebola epidemic.

Sierra Leone launches controversial Ebola shutdown

Sep 19, 2014

Sierra Leone on Friday launched a controversial three-day shutdown to contain the deadly spread of the Ebola virus, as the UN Security Council declared the deadly outbreak a threat to world peace.

User comments